BUSINESS

• MSD Files 2 Antivirals for Hep C Treatment in Japan
  March 14, 2016

• Ono Beefing Up Organization for Safe Use of Opdivo, Eyes Larger Cancer Sales Force
  March 11, 2016

• Mitsubishi Tanabe to Solely Market Janssen’s Simponi in Japan
  March 11, 2016

• Takecab Most Heavily Pitched Drug in January: Anterio
  March 11, 2016

• Re-Pricing, Z2, Deferred Price Cuts Hammering Mainstay Drugs, Otsuka Sees Double-Digit Reductions for Top 5 Sellers: Tally
  March 9, 2016

• Japan Generic Market to Reach 1.1 Trillion Yen in 2018: Fuji Keizai
  March 9, 2016

• Nemolizumab Shows Efficacy for Atopic Dermatitis in Global PII: Chugai
  March 8, 2016

• Sandoz Suffers Hefty 20% Price Cuts in FY2016 Revision, Teva 8.3%: Jiho Survey
  March 8, 2016

• Kyowa Kirin Expects to Double Sales Force in US to Build Independent Marketing System; Anticipates Launch of Parkinson’s Drug in 2018
  March 8, 2016

• Toyama Chemical Sues 3 Generic Firms over Ozex Patent
  March 8, 2016

• Debiopharm Wins Elplat Patent Suit against Nippon Kayaku
  March 8, 2016

• Z2 Price Cut Rule to Smash Mitsubishi Tanabe, Astellas, Pfizer: Jiho Tally
  March 7, 2016

• Drug Price Cut to Net Out at 5.5% for Chugai, Gilead to Suffer 31.65% in Full: Jiho Tally
  March 7, 2016

• Japan NDA Filed for Anti-HIV Drug Genvoya
  March 7, 2016

• NHI Price Reduction Rates for Plavix Generics to Vary Largely between 17.1% and 59.5%: Jiho Tally
  March 7, 2016

• Eisai Looks to Log Over 800 Billion Yen in FY2020, Lenvima as Key Growth Engine
  March 4, 2016

• Teva Pharma Japan Voluntarily Recalling 7 Products
  March 3, 2016

• Public Knowledge-Based Application Filed for Xeloda as Adjuvant Chemotherapy for Rectal Cancer: Chugai
  March 3, 2016

• Pfizer Japan Chief Frets Possible Decline in Foreign Investments amid Anti-Innovation Drug Policies
  March 3, 2016

• Pfizer’s Japan Sales Tick Up 2% in FY2015
  March 3, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 466
• 467
• 468
• 469
• 470
• 471
• 472
• 473
• 474
• …
• Next ›
• 最終 »